Nová - přímá perorální antikoagulancia: aktuální přehled
[New - direct oral anticoagulants: actual review]
Language Czech Country Czech Republic Media print
Document type Journal Article, Review
PubMed
27900867
PII: 59673
- MeSH
- Antidotes MeSH
- Anticoagulants therapeutic use MeSH
- Antithrombins therapeutic use MeSH
- Administration, Oral MeSH
- Dabigatran therapeutic use MeSH
- Antibodies, Monoclonal, Humanized therapeutic use MeSH
- Factor Xa Inhibitors therapeutic use MeSH
- Hemorrhage chemically induced drug therapy MeSH
- Humans MeSH
- Pyrazoles therapeutic use MeSH
- Pyridones therapeutic use MeSH
- Rivaroxaban therapeutic use MeSH
- Practice Guidelines as Topic MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Antidotes MeSH
- Anticoagulants MeSH
- Antithrombins MeSH
- apixaban MeSH Browser
- Dabigatran MeSH
- Antibodies, Monoclonal, Humanized MeSH
- idarucizumab MeSH Browser
- Factor Xa Inhibitors MeSH
- Pyrazoles MeSH
- Pyridones MeSH
- Rivaroxaban MeSH
In recent years the options of anticoagulant/antithrombotic therapy have extended with new - direct oral anticoagulants, comprising direct thrombin inhibitors (dabigatran etexilate) and direct factor Xa inhibitors (rivaroxaban, apixaban). These agents represent another progress towards "the ideal antithrombotic drug", and thus towards a safe and effective antithrombotic therapy. The following article provides actual review and recommendations for clinical practice, including laboratory assessment and management of emergency situations. The approval of idarucizumab as a specific antidote for dabigatran has marked an important step in safety of this treatment.Key words: apixaban - dabigatran - DOAC - NOAC - rivaroxaban.
